Author Archives: admin

Value of medicines is number one concern for oncologists

Financial impact and affordability of medicines is the number one concern for oncologists in our 2019 Leadership research in ImmunoOncology. Oncologists were asked to choose their top three areas (from a list of fourteen attributes) for corporate leaders to improve most over the next few years.Most Wanted Areas of Improvement for Corporate Leaders in ImmunoOncology - Financial impact

The sentiment is especially pronounced in the United States where almost half (47%) of the surveyed oncologists worry about the financial impact of oncology medications on the healthcare system and patients. In Europe, the concerns are also shared by a large group of oncologists (37%), and equally viewed as the most concerning aspect affecting corporate leadership moving forward. This coincides with the debate on the value of medicines picking up speed on both continents, and in Europe, more regulators and payors are working together on joint HTA assessments and cross-border purchasing (e.g. BeNeLuxA initiative).

While financial considerations do not materially influence treatment decisions of oncologists, the rising cost of medications is an ever-present worry. The surveyed oncologists fear insufficient value may have a toxic financial effect on the overall healthcare system.

Earlier and accelerated access

Oncologists in our research would like to see better and earlier access to innovative treatments for their patients.

In line with our findings from last week, MDoutlook - Oncologist Views on Areas of Improvement in Corporate Leadership patient support programs play an important role in making a difference for patients. Aligning your patient support program with the needs of healthcare professionals while further help to alleviate widely held concerns of “financial toxicity”. Communications and marketing functions also need to improve their messages and materials to better communicate value – see our detailed analysis to the right.
Follow our future releases to find out more about better stakeholder management and engagement using digital tools.

Key takeaways:

  • Value of cancer medicines is primary concern for oncologists
  • Early access schemes do make a difference to patients
  • Align patient support programs with value messaging

About the study

The 2019 Leadership Study was conducted with 100 oncologists across US and EU using MDoutlook’s proprietary ONCpulse™ service.

The research objectives were to:

  • Define the meaning of “corporate leadership” to the oncology community
  • Reveal the leaders in oncology and ImmunoOncology (IO) and to compare / contrast how companies are evaluated by oncologists
  • Assess current drivers & barriers to ImmunoOncology treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space

Please contact us if you wish to be included in the distribution of the study.

Click on image to enlarge

1 in 3 oncologists do not have a clear leader in patient support programs

Our 2019 Leadership study in ImmunoOncology shows that 1 in 3 oncologists (across the US and EU) are not sufficiently aware of different patient support programs. While oncologists most often recall the patient support programs by BMS, Roche/Genentech and Merck there is no overall corporate leader.

Leader in Oncology Patient Support Programs

Click on image to enlarge

Patient support programs can play a vital part in increasing access to medications and help to improve patient compliance to treatments. Providing improved access to medicines and helping patients in their treatment journey are cornerstones of the current debate around high price ImmunoOncology therapies.

Healthcare professionals have consistently highlighted the financial impact for patients and limited access to innovative medicines as their main concerns in our study. The findings of our study provide an important impetus for patient facing functions such as public affairs and patient advocacy teams to improve recall with healthcare professionals in institutional settings.

Our study will further provide you with better insights and ideas to increase awareness of your patient support program.

About the study

The 2019 Leadership Study was conducted with 100 oncologists across US and EU using MDoutlook’s proprietary ONCpulse™ service.

The research objectives were to:

  • Define the meaning of “corporate leadership” to the oncology community
  • Reveal the leaders in oncology and ImmunoOncology (IO) and to compare / contrast how companies are evaluated by oncologists
  • Assess current drivers & barriers to ImmunoOncology treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space

Please contact us if you wish to be included in the distribution of the study.

Oncologists value Bio-Pharma’s commercial and marketing activities

Having revealed the top attributes for successful leadership in ImmunoOncology, MDoutlook’s latest release reveals that specific commercial and marketing activities influence about 25% of oncologists’ leadership criteria.

Click on image to enlarge

Click on image to enlarge

As important criteria for steering successful leadership reputation, oncologists rated the following specific commercial and marketing activities in order of impact.

  1. Length of time in market
  2. Corporate reputation
  3. Medical educational activities
  4. Patient access (affordability and availability)
  5. Patient support programs
  6. Supportive tools / services for healthcare professionals
  7. Promotional educational activities
  8. Sales representatives and MSLs
  9. Supportive digital health solutions

Subtle geographical differences were observed. US oncologist favored “longevity”, “corporate reputation” and “patient access (affordability / availability) to treatments”. EU based oncologists stressed more importance on “medical educational activities” and “supportive tools and services for healthcare professionals”.

To gain richer insight and understanding for your organization and your competitors, we analyzed performance by each attribute based on oncologist perspectives with their chosen life science companies. Get in touch to find out how your company and your competitors performed.

In a future release, we will explore specific attributes revealing company performance and opportunity.

About the study

The 2019 Leadership Study was conducted with 100 oncologists across US and EU using MDoutlook’s proprietary ONCpulse™ service.

The research objectives were to:

  • Define the meaning of “corporate leadership” to the oncology community
  • Reveal the leaders in oncology and ImmunoOncology (IO) and to compare / contrast how companies are evaluated by oncologists
  • Assess current drivers & barriers to ImmunoOncology treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space

Please contact us if you wish to be included in the distribution of the study.

How oncologists view leadership in ImmunoOncology

In our latest release from the 2019 Leadership study, we reveal 7 key attributes that account for 75% of Oncologists’ definition of leadership in ImmunoOncology (IO).

Oncology Leadership Factors

Click on image to enlarge

These attributes comprise R&D / pipeline and product related aspects of life science company activities.

We found high consistency across geography. However, EU oncologists placed greater emphasis on “clinical trials & research grants” and “integration of biomarkers and diagnostics” compared to their US colleagues.

The attributes are in order of overall impact:

  1. Number of approvals (cancer types & lines of therapy)
  2. Number of different IO products available within portfolio
  3. Development of combination therapies with IO
  4. Clinical trials and research grants
  5. Integration of biomarkers and diagnostics
  6. Differentiation from other IO offerings
  7. Value proposition of product portfolio

For each of these attributes we analyze performance by life science companies. Get in touch to find out how your company and your competitors performed.

In our next release, we will explore the remaining attributes and reveal the relative importance of specific commercial and marketing activities to oncologists when defining leadership.

About the study

The 2019 Leadership Study was conducted with 100 oncologists across US and EU using MDoutlook’s proprietary ONCpulse™ service. The research objectives were to:

  • Define the meaning of “corporate leadership” to the oncology community
  • Reveal the leaders in oncology and ImmunoOncology (IO) and to compare / contrast how companies are evaluated by oncologists
  • Assess current drivers & barriers to ImmunoOncology treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space

Please contact us if you wish to be included in the distribution of the study.

2019 Leadership Study in Oncology & ImmunoOncology

Later this month, MDoutlook will release results from the latest wave of their global leadership study.

Using ONCpulse™, we engaged with a robust sample of oncologists located in the United States and Europe. The research objectives were to:

  • Define the meaning of “corporate leadership” to the oncology community
  • Reveal the leaders in oncology and ImmunoOncology (IO) and to compare / contrast how companies are evaluated by oncologists
  • Assess current drivers & barriers to ImmunoOncology treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space

Early results reveal the top 3 companies in Oncology and ImmunoOncology. Oncology Leadership Top 3

Across tumor types, BMS were rated as the top ImmunoOncology leader in 9 out of the 12 areas covered. Oncologists favored Roche & Merck highest in breast cancer (Roche); bladder cancer (Roche & Merck) and NSCLC (Merck).

ImmunoOncology Leadership across tumors

Oncologists chose to rate leadership across a greater number of companies in the broader oncology arena compared to a tighter list of companies they rated in ImmunoOncology.

Seventy percent of US oncologists viewed leadership success across tumor types than in any one specific area (30% respondents). This view was stronger when compared to the split picture (49% vs 51% respectively) presented by EU-based oncologists.

More information about the 2019 Leadership Study will become available as we publish the read-out results. Please contact us if you wish to be included in the distribution of the study.

ONCpulse™ – Precision Oncology In Action

ONCpulse™ recently provided time sensitive feedback from Oncologists’ review of messaging from a TPP project in metastatic Gastric Cancer. Reflecting on the study, the Director of Market Research Oncology of this large biopharmaceutical client reported (Jan 2019): “This is great! Thanks. I appreciate the quick turnaround and will discuss the results with my ad agency on Wednesday.”

Read below a data point example on how we provided insights.

Client need:

  • To obtain immediate feedback and ratings on statements to support a messaging campaign in metastatic Gastric Cancer (mGC)
  • To gauge reactions to new positioning statements from Oncologists treating a large number of patients with mGC

Project Delivered:

  • ONCpulse provided timely insights from more than 50 qualified US based Oncologists
  • Delivered within 72 hours
  • Custom quantitative study with fully analyzed results, produced by MD/PhD oncology-experienced analysts

Results Achieved:

  • Making confident business decisions with messaging choicesONCpulse Insights in mGC
  • Shortened development of new messages and provided strong direction for next steps with their ad agency
  • Created time and financial efficiencies to meet their planned timetable and budget

More information about ONCpulse can be found here. Contact us now to learn how we can help you improve your company’s decision making in today’s expansive and disruptive oncology environment.

 

ONCpulse™ launched: rapid on-demand custom insights

We are thrilled to announce the launch of our newest subscription service: ONCpulse™. Realizing that many of our clients struggle with obtaining rapid insights to improve their decision-making, MDoutlook has developed ONCpulse.

ONCpulse delivers rapid, on-demand insights from verified, high quality cancer treaters and experts: ONCpulse
Rapid: Delivering actionable insights within 72 hours
Right: Engaging verified, high-quality cancer treaters and experts
Reach: Covers all cancers and geographies, accessing more than 100,000 cancer treaters globally
Relevant: Answers your specific questions through customized questions

Clients pre-purchase a set research bank of insights that they can implement on-demand. This drives transparency, eases client operations, creates flexibility in timing and scope, and most importantly delivers clients the desired, actionable insights within 72 hours. ONCpulse utilized proprietary assets including the MDoutlook network and technology.

For more information, view the ONCpulse page here, and contact the ONCpulse team at [email protected] or +1.404.496.4136.

Good Question – PM360 Guest Commentary

Our President and Founder, Jan Heybroek, was invited by PM360 to comment on recent concerns about the quality of (oncology) market research. The need to quickly track new product performance in priority markets is a key driver for this anxiety. This is relevant since standard prescription data, multi-disciplinary patient management, and varied institutional settings provide a scattered picture of the oncology market.

The industry can take major steps to ensure receipt of impeccable oncology market intelligence on a consistent basis. Jan provides 6 key measures to consider. Read his full column in PM360.

For more information on how MDoutlook provides impeccable and actionable disease intelligence, navigate our site and contact us here.

 

Rapid and Actionable Insights on Clinical Impact of ESMO 2017

After every major conference, MDoutlook provides valuable insights to our clients on the impact of new data presented. With the 2017 ESMO conference here, we are planning a series of syndicated studies. Final disease focus will be updated following our analysts’ review of new data presented.

As an example of syndicated research coming out of this year’s ASCO, please click on the images below for an overview of typical structure and contents of our Rapid Insights reports, and 2 insight slides.

If you would like to participate in the ESMO research or receive more details about our rapid conference insight reports, contact us by calling +1.404.496.4136 or dropping us a line here.

Contents of MDoutlook Rapid Insights Reports

MDoutlook_Rapid Insights Report Contents

Source of Abstract Awareness

MDoutlook_ASCO 2017 Abstract Source of Awareness

Physician Time on ASCO Exhibit Floor

MDoutlook_ASCO 2017 Exhibit Attendance

Case Study: Competitive Treatment Driver Analysis

At MDoutlook, we focus on providing actionable insights to our clients. These insights can provide valuable data to improve market share and compare and contrast our client’s products to those of their competition. Below is a case study outlining the main reasons taxanes are not considered for use following paclitaxel treatment in ovarian cancer.

Customer: Global pharmaceutical company expanding their disease portfolio into new therapeutic areas.

Challenge: Client needed to compare and contrast treatment decision drivers between competitive therapies as input for their clinical development and commercialization planning.

Unique MDoutlook proposition: 

  • Develop comprehensive questionnaire to address both quantitative treatment market share analysis while differentiating qualitative decision driver attributes often retrieved by different research methodologies (e.g. qualitative)
  • Panel Composition: 100 screened ovarian cancer treaters
  • Comparative Analysis:
    • By competitive therapies
    • Academic vs. community practice

Value delivered: 

  • Actionable insights to guide patient segmentation, commercial positioning and messaging
  • Robust and projectable quantitative market share analysis
  • Sophisticated qualitative insights generated by a quantitative study methodology that increased the study efficiencies and shortened the study timeline

Send an email to [email protected] to learn more.

july email image